Does diabetes mellitus affect the safety profile of valproic acid for the treatment of status epilepticus? A retrospective cohort study

Annekatrin Müller1*, Judith von Hofen-Hohloch1, Carolin Awissus1, Jens Przybilla2, Achmed Mrestani1 and Joseph Classen1

Abstract

Background: In the treatment of status epilepticus less is known about the influence of comorbidities on the safety profile of anticonvulsive drugs. Especially patients with diabetes mellitus may be predisposed to certain adverse events that have been related to therapy with valproic acid. In this single-center retrospective cohort study we examined if the complications of the intravenous treatment with valproic acid is different in patients with or without diabetes.

Methods: Patients who were treated for status epilepticus with intravenous valproic acid between 2008 and 2020 were identified. Primary endpoint was the discontinuation of therapy with valproic acid due to adverse events. Relevant secondary endpoints were the functional status at the time of discharge from hospital in comparison to the premorbid state and the in-hospital mortality. Both groups (patients with or without diabetes) were compared by Mann–Whitney U-test or Pearson’s Chi² test. To identify therapy with valproic acid as a risk factor of in-hospital mortality, a binary regression model was used.

Results: During the study period 408 patients and 482 episodes of status epilepticus were treated with intravenous valproic acid. Group comparisons did not reveal a significant difference in the rates of discontinuation of therapy. A difference was found in the rate of thrombocytopenia ($p = 0.015$), which occurred more often in patients with diabetes. In total, 36 hypoglycemic episodes could be identified, two occurred spontaneously under intravenous valproic acid. After correction for potential confounders, continuous therapy with valproic acid could not be confirmed as an independent risk factor for in-hospital mortality ($p = 0.079$). In patients with diabetes, the proportion of patients with a good functional state, indicated by the modified Rankin Scale, was significantly lower in both times (premorbid: 55% vs. 69%, $p = 0.008$; at discharge: 22% vs. 36%, $p = 0.004$).

Conclusions: Tolerability of the treatment with valproic acid was similar in patients with or without diabetes. Diabetes as a relevant comorbidity can signal a potentially increased risk of a poor outcome after status epilepticus.

Trial registration: The study was registered at the German Clinical Trials Register on 8 April 2022 (DRKS 00,027,836).
Background
Status epilepticus (SE) is after stroke the most frequent neurological emergency condition with case fatality rates of about 15% [1]. Previous research has focused on potential prognostic factors of SE, including age, etiologies and therapeutic regimes [2–4]. With regard to antiepileptic drugs, efficacy and the general safety profile have been reported [e.g., 5]. However, to our knowledge, no analysis has been performed on the influence of individual comorbidities on the safety of specific antiepileptic drugs.

Valproic acid (VPA) is an established therapy for the treatment of SE in Germany and many other European countries [6]. It is recommended as one of the second line drugs after failure of benzodiazepines. According to the most recent guidelines from Italy and Germany, additional second-line therapies for the treatment of SE include levetiracetam and (fos)phenytoin [7, 8]. Published data reveal a good safety profile of VPA even in critically ill patients [5, 9]. No safety signals have emerged from international published safety studies or other trials (reviewed in Trinka et al., 2014 [5]) including the prospective Established Status Epilepticus Treatment Trial [ESETT; 9, 10]. On the other hand, patients with certain comorbidities have not been considered separately. However, treatment with VPA is known to be associated with adverse events that may occur more frequently in specific risk populations.

Here, we asked whether the safety profile of intravenous (IV) VPA treatment of SE is modulated by the presence or absence of diabetes mellitus, particularly insulin-dependent diabetes mellitus (IDDM). Our question was motivated by the increasing frequency of diabetes in the general population [11]. Furthermore, VPA is associated with adverse events to which patients with diabetes are predisposed, such as disturbance of the glucose metabolism or pancreatic damage.

Therefore, the present retrospective study in a single-academic center cohort examined if, all other available factors considered, complications of IV treatment with VPA were different in patients with and without known concomitant diabetes. Outcome relevant issues included the in-hospital mortality and the modified Rankin Scale [mRS, 12] at the time of discharge from hospital.

Methods/design
Study design
The present study was conducted in a retrospective, non-interventional design (DRKS 00,027,836). It was approved by the local Ethics Committee (05/2021; 227/21-ek).

Keywords: Status epilepticus, Valproic acid, Diabetes mellitus, Safety
several of the following conditions diagnosed by the treating team: disturbance of consciousness (which could not be strictly related to an ictal or postictal state in the opinion of the medical staff), thrombocytopenia, parkinsonism, elevation of liver enzymes, bleeding, others. Thrombocytopenia was attributed to the therapy with VPA, if (1) platelet levels were normal before IV administration of VPA OR (2) there was an aggravation of a pre-existing thrombocytopenia under IV VPA and previous oral maintenance therapy with VPA AND platelet levels recovered after withdrawal from therapy. In addition, other complications of in-hospital treatment that may be attributed to VPA therapy were obtained from the hospital records: need for mechanical ventilation, bleedings that required intervention and/or blood transfusion, episodes of hypoglycemia (single vs. recurrent, blood glucose level < 3.3 mmol/L) and severe pancreatic damage.

Outcome definitions
Primary endpoint was the rate of discontinuation of the VPA therapy due to adverse events. Secondary endpoints were: need for mechanical ventilation, episodes of hypoglycemia, bleedings that require intervention, pancreatic damage, rate of in-hospital mortality associated with continuous or repeated VPA infusions, and the functional status at discharge from hospital as indicated by the mRS in comparison with the premorbid mRS. Primary and secondary endpoints were assessed in patients with and without diabetes. The outcome parameters (functional status at discharge from hospital and mortality) were also assessed in the total cohort.

Statistical analysis
For statistical analysis, we considered the first SE episode from each patient which was treated with VPA. The study cohort was described by median and interquartile range for continuous and number (percent) for categorical characteristics. Accordingly, groups were compared by Mann–Whitney U-test. Categorical variables were compared using the Pearson’s Chi² test or the Fisher’s exact test. To identify VPA therapy as a potential risk factor of in-hospital mortality, the binary logistic regression model was used. Variables included in the model were selected based on a preceding univariate analysis. Only variables showing a significant difference in univariate analysis were considered candidate covariates for the multivariate model.

In case of a significantly different occurrence of an adverse event, we corrected the result for age and sex also using a binary regression model. For the comparison of the premorbid functional state with the functional outcome at discharge, only patients in whom both mRS values were available were considered. Analysis was performed using the Wilcoxon test for paired samples. To investigate the interaction between group assignment (diabetic vs. non-diabetic, between subject factor) and the point in time of mRS determination (within subject factor), mixed ANOVA analysis was performed. The general significance level was set at α = 5% for two-tailed testing. Data preparation, descriptive statistics, correlation analysis and nonparametric tests were performed with IBM SPSS Statistics, version 27 and 28. Illustrations were created with Microsoft Power Point, SigmaPlot 13.0 and Adobe Illustrator 2020 24.0.1.

Results
Demographic and clinical characteristics of the study cohort
We identified 807 patients who were treated in the Department of Neurology at Leipzig University Hospital between 2008 and 2020 and whose hospital records were coded as SE. In this group, 408 patients, in whom the diagnosis of SE was verified using the criteria outlined in “Methods”, received VPA via an IV route. A total of 482 episodes of SE treated with IV VPA were identified (Fig. 1). Concomitant diabetes was known in 133 patients including 55 patients with IDDM (13%). The median age of the total cohort was 73 years (62–81 years). The majority of patients (90%) were treated with VPA either continuously or with repeated infusions. Regarding dosage and time of start, no significant differences between
the group of patients with or without diabetes could be found (Additional file 1).

The main clinical characteristics including relevant adverse events potentially related to VPA therapy are listed in Table 1.

Table 1 Characteristics of the total study cohort and both groups (patients with or without known diabetes)

| Characteristics                        | Total cohort | Group, diabetes | Group, no diabetes | p-value |
|----------------------------------------|--------------|-----------------|--------------------|---------|
| Patients                               | N = 408      | N = 133         | N = 275            |         |
| **Demographics**                       |              |                 |                    |         |
| Age                                    | 73 (62–81)   | 75 (70–81)      | 71 (58–81)         | 0.001   |
| Sex: m (male) f (female)               | m 188 (46%), f 220 (54%) | m 51 (38%), f 82 (62%) | m 137 (50%), f 138 (50%) | 0.034   |
| **Comorbidities**                      |              |                 |                    |         |
| Charlson Comorbidity Index             | 3 (1–4)      | 4 (3–6)         | 2 (1–3)            | <0.001  |
| Insulin-dependent diabetes mellitus    | 55 (14%)     | 55 (42%)        | 0                  | <0.001  |
| Active abuse of alcohol*               | 41 (10%)     | 10 (8%)         | 31 (11%)           | 0.293   |
| **Status epilepticus**                 |              |                 |                    |         |
| STESS ≥ 3                              | 272 (67%)    | 106 (80%)       | 166 (60%)          | <0.001  |
| Worst seizure type: GCSE               | 171 (42%)    | 47 (35%)        | 124 (45%)          | 0.061   |
| Worst seizure type: NCSE with coma*    | 12 (3%)      | 3 (2%)          | 9 (3%)             | 0.758   |
| Consciousness: Stuporous or comatose   | 306 (75%)    | 99 (74%)        | 207 (75%)          | 0.855   |
| History of seizures                    | 202 (50%)    | 48 (36%)        | 154 (55%)          | <0.001  |
| **Etiology of SE**                     |              |                 |                    |         |
| Potentially fatal etiology             | 126 (31%)    | 47 (35%)        | 79 (29%)           | 0.175   |
| **Treatment with VPA**                 |              |                 |                    |         |
| VPA single infusion*                   | 42 (10%)     | 10 (8%)         | 32 (12%)           | 0.227   |
| VPA repeated or continuous infusion    | 366 (90%)    | 123 (93%)       | 243 (88%)          | 0.200   |
| Stop treatment with VPA                | 147 (36%)    | 52 (39%)        | 95 (33%)           | 0.369   |
| Reason: adverse events                 | 53 (13%)     | 22 (17%)        | 31 (11%)           | 0.138   |
| Reason: interaction of medication*     | 24 (6%)      | 7 (5%)          | 17 (6%)            | 0.825   |
| Other reasons, no adverse events       | 70 (17%)     | 23 (17%)        | 47 (17%)           | 0.886   |
| **Adverse events**                     |              |                 |                    |         |
| Disturbance of consciousness*          | 27 (7%)      | 11 (8%)         | 16 (6%)            | 0.397   |
| Thrombocytopenia*                      | 8 (2%)       | 6 (5%)          | 2 (1%)             | 0.017   |
| Parkinsonism*                         | 1 (0.2%)     | 1 (1%)          | 0                  | 0.326   |
| Elevation of liver enzymes*            | 7 (2%)       | 2 (2%)          | 5 (2%)             | 1.0     |
| Bleeding*                              | 2 (0.5%)     | 0               | 2 (1%)             | 0.559   |
| Others*                                | 8 (2%)       | 2 (2%)          | 6 (2%)             | 1.0     |
| **In-hospital complications**          |              |                 |                    |         |
| Need for mechanical ventilation        | 180 (44%)    | 52 (39%)        | 128 (47%)          | 0.156   |
| Episodes of hypoglycemia*              | 11 (3%)      | 8 (6%)          | 3 (1%)             | 0.009   |
| Bleeding with intervention*            | 20 (5%)      | 7 (5%)          | 13 (5%)            | 0.810   |
| Pancreatic damage*                     | 3 (1%)       | 1 (1%)          | 2 (1%)             | 0.546   |
| **Outcome**                            |              |                 |                    |         |
| In-hospital mortality                   | 65 (16%)     | 26 (20%)        | 39 (14%)           | 0.165   |
| In-hospital mortality after recurrent SE* | 6/74 (8%) | 0/27           | 6/47 (13%)         | 0.080   |
| mRS at discharge                       | 4 (3–5)      | 5 (4–5)         | 4 (3–5)            | 0.004   |

Adverse events during the treatment with VPA and intrahospital complications of patients with or without diabetes

In 14% of the patients, treatment with VPA was stopped due to safety concerns. The most frequent reason for

Metric variables are described with median and interquartile range, categorical variables in number and percentage. Continuous variables were compared using Mann–Whitney U test. Proportions were compared using Pearson’s Chi2 test or Fisher’s exact test (*). Statistically significant values (p < 0.05) are expressed in bold.

In another three patients VPA was stopped because of the aggravation of a pre-existing thrombocytopenia

Bold indicates comparison of characteristics between both groups

STESS status epilepticus severity score; GCSE generalized convulsive status epilepticus; NCSE nonconvulsive status epilepticus; VPA valproic acid; SE status epilepticus; mRS modified Rankin scale
withdrawal of therapy was a disturbance of consciousness (7%).

Univariate analyses revealed no significant difference between the rates of discontinuation in the two groups of patients with or without diabetes (Table 1). The detailed examination of adverse events showed a difference in the rate of thrombocytopenia which was higher in patients with diabetes than in patients without diabetes (5% vs. 1%). The difference remained significant after correction for age and sex in a binary logistic regression model (p = 0.015). We also examined the rate of withdrawal of therapy due to concerns about comorbidities or potential adverse events. Those were: thrombocytopenia in the past, aggravation of a known hepatic damage, known osteoporosis, aggravation of hyponatremia, and abuse of alcohol. Therapy with VPA was not stopped more frequently in patients with diabetes because of the concerns mentioned above (p = 0.435).

For further evaluation, we also examined the incidence of adverse events in recurrent SE episodes. Out of 408 patients, 61 patients suffered between one and a maximum of four SE episodes treated with IV VPA. In recurrent episodes, there were no significant differences between both groups, either in the rates of discontinuation of therapy or in the rate of specific adverse events including thrombocytopenia (p = 0.365, Table 2).

In the entire cohort and across all SE episodes, a total of 36 hypoglycemic episodes occurred. Out of these, two episodes occurred spontaneously during the therapy with IV VPA, i.e., there was no antidiabetic medication or other known etiology that may predispose to hypoglycemia (such as liver cirrhosis). In one patient without known diabetes, a hypoglycemic episode occurred spontaneously five days after the termination of VPA (Additional file 2).

Within the diabetic group (N = 133), 55 patients were diagnosed with IDDM. Comparison of the two subgroups (patients with or without IDDM) revealed no significant difference in the rate of discontinuation of therapy with VPA or the rate of adverse events (Additional file 3).

### In-hospital mortality and outcome at hospital discharge
Sixty-five of 408 patients (16%) died in hospital. Univariate analysis revealed that patients who died in hospital were treated more often with VPA continuously or with repeated infusions (97%) than patients who survived (88%, p = 0.043, Table 3). Potential confounders identified in univariate analyses (age, sex, premorbid mRS, CCI, STESS ≥ 3, potentially fatal etiology, and need for mechanical ventilation) were integrated in a binary logistic regression model. Also, diabetes as covariate was forced into the model. After adjustment for the respective confounders, therapy with IV VPA was not confirmed as an independent risk factor for in-hospital mortality (p = 0.079, Additional file 4). In a second step, we repeated the univariate analysis for the group of patients with diabetes. The proportions of patients treated with VPA continuously or in repeated infusions did not differ significantly between the group of patients who died in hospital (100%) and those who survived (91%, p = 0.209; Additional file 5).

The functional state, as measured by the mRS, deteriorated significantly between the time before the hospital stay and the time at discharge from hospital both in the

Table 2: Adverse events in recurrent SE episodes of the total study cohort and both groups (patients with or without diabetes)

| Characteristics                      | Recurrent SE | Group, diabetes | Group, no diabetes | p-value |
|--------------------------------------|--------------|----------------|-------------------|---------|
| Episodes                             | N = 74       | N = 27         | N = 47            |         |
| Stop treatment with VPA              | 19 (26%)     | 6 (22%)        | 13 (28%)          | 0.606   |
| Reason: adverse events*              | 6 (8%)       | 3 (11%)        | 3 (6%)            | 0.662   |
| Reason: interaction of medication*   | 5 (7%)       | 1 (4%)         | 4 (9%)            | 0.647   |
| Other reasons, no adverse events*    | 8 (11%)      | 2 (7%)         | 6 (13%)           | 0.702   |
| Adverse events                       |              |                |                   |         |
| Disturbance of consciousness*        | 2 (3%)       | 1 (4%)         | 1 (2%)            | 1.0     |
| Thrombocytopenia*                    | 1 (1%)       | 1 (4%)         | 0                 | 0.365   |
| Parkinsonism*                        | 0            | 0              | 0                 | /       |
| Elevation of liver enzymes*          | 1 (1%)       | 0              | 1 (2%)            | 1.0     |
| Bleeding*                            | 0            | 0              | 0                 | /       |
| Others*                              | 2 (3%)       | 1 (4%)         | 1 (2%)            | 1.0     |

In another SE episode VPA was stopped due to an aggravation of a pre-existing thrombocytopenia

Categorical variables were described with number and percentage. Proportions were compared using Pearson’s Chi2 test or Fisher’s exact test (*). Statistically significant values (p < 0.05) are expressed in bold

SE status epilepticus; VPA valproic acid
total cohort (N = 366; p < 0.001) and in the two groups (diabetic group: N = 124, p < 0.001, non-diabetic group: N = 242; p < 0.001). In terms of the proportion of patients with good functional state (mRS 0–3), a significant difference between the diabetic and non-diabetic group could be found in both times: before hospitalization (55% vs. 69%, p = 0.008) and at discharge (22% vs. 36%, p = 0.004).

To further assess the change in functional status during the hospital stay, we compared the differences of the mRS scores between the patients with and without known diabetes. No significant differences could be found (p = 0.948). Also, there was no statistically significant interaction between the point in time of mRS determination and group assignment (diabetes vs. non-diabetic; F[1, 364] = 0.026, p = 0.873, partial η² < 0.001). The distribution of the premorbid mRS and the functional state at discharge in both groups are illustrated in Fig. 2.

The significant difference of proportions of patients with good functional state before hospitalization and at time of hospital discharge was not reproduced in the separate analysis of the diabetic group: patients with IDDM (N = 50) vs. patients without IDDM (N = 74); premorbid mRS 58% vs. 53%, p = 0.586; mRS at time of discharge 26% vs. 19%, p = 0.381.

**Table 3** Factors associated with in-hospital mortality: total study cohort

| Characteristics                                      | In-hospital mortality | Survival of hospital | p-value |
|------------------------------------------------------|-----------------------|----------------------|---------|
| Patients                                             | N = 65                | N = 343              |         |
| Demographics                                         |                       |                      |         |
| Age                                                  | 79 (71–87)            | 72 (60–80)           | <0.001  |
| Sex m (male) f (female)                              | m 21 (32%) f 44 (68%) | m 167 (49%) f 176 (51%) | 0.015   |
| Premorbid mRS                                        | 4 (2 –4)              | 3 (1 –4)             | 0.004   |
| Comorbidities                                        |                       |                      |         |
| Charlson Comorbidity Index                           | 4 (3–6)               | 3 (1–4)              | <0.001  |
| Diabetes mellitus                                    | 26 (40%)              | 107 (31%)            | 0.165   |
| Insulin-dependent diabetes mellitus                  | 7 (11%)               | 48 (14%)             | 0.511   |
| Status epilepticus (SE)                              |                       |                      |         |
| STESS ≥ 3                                            | 60 (92%)              | 212 (62%)            | <0.001  |
| Etiology of SE                                       |                       |                      | <0.001  |
| Potentially fatal etiology                           | 44 (68%)              | 82 (24%)             |         |
| Treatment with VPA                                   |                       |                      |         |
| VPA single infusion*                                  | 2 (3%)                | 40 (12%)             | 0.037   |
| VPA repeated or continuous infusion                  | 63 (97%)              | 303 (88%)            | 0.037   |
| In-hospital complications                            |                       |                      |         |
| Need for mechanical ventilation                      | 37 (57%)              | 143 (42%)            | 0.023   |
| Episodes of hypoglycemia*                            | 3 (5%)                | 9 (3%)               | 0.416   |
| Bleeding with intervention*                          | 2 (3%)                | 18 (5%)              | 0.753   |

Metric variables are described with median and interquartile range, categorical variables in number and percentage. Continuous variables were compared using Mann–Whitney U test. Proportions were compared using Pearson’s Chi² test or Fisher’s exact test (*). Statistically significant values (p < 0.05) are expressed in bold.

mRS modified Rankin scale; STESS status epilepticus severity score; SE status epilepticus; VPA valproic acid

**Fig. 2** Distribution of mRS scores in both groups patients with or without diabetes. Abbreviations: mRS, modified Rankin Scale

**Discussion**

In this retrospective single-center cohort study, we investigated the safety profile of IV VPA in patients with SE focusing on diabetes as a significant and increasingly prevalent comorbidity especially in the elderly population [17, 18]. By including information about this group, the present study complements previous prospective and retrospective trials on the treatment of SE. So far,
we have identified only a few studies that considered the impact of comorbidities in the prognosis of SE [4, 19–23].

Our results demonstrate that the rates of discontinuation of VPA therapy do not differ significantly between the diabetic and non-diabetic group. Analysis of individual recurrent SE episodes did not reveal a signal of cumulative toxicity, though the sample size was small. The incidence of adverse events detected in the total cohort was marginally higher than reported in the literature [5]. The difference may be fully explained by the high age of patients (median, 73 years) as advanced age is associated with lower resistance to complications. Regarding safety concerns, a disturbance of consciousness was the most frequent reason leading to discontinuation of treatment. This is in accordance with other studies [9, 24]. Interestingly, the difference in the occurrence of thrombocytopenia remained significant to the disadvantage of the diabetic group even after correction for age and sex. According to previous work, (auto)-immune processes secondary to viral infections [25] or heparin-treatment [26] may play a role in the pathogenesis of thrombocytopenia. A similar mechanism may be operative in the pathogenesis of VPA-induced reduction of platelet counts [27]. Therefore, it seems reasonable to expect that treatment with VPA carries a higher risk of thrombocytopenia with concomitant diabetes. The risk may be enhanced by other predisposing factors (i.e., sepsis). Considering the small number of cases (5% and 2%) the clinical relevance must be assessed individually for each clinical situation.

Long term therapy with VPA is known to cause overweight and hyperglycemia [28–30]. On the other hand, studies in a diabetic rat model or in mice revealed a reduction of insulin resistance and an enhanced insulin- action under short term (10 weeks) or acute treatment with VPA, respectively [31, 32]. In our study, the frequency of hypoglycaemia during VPA treatment and the number of SE episodes were too low to either refute or confirm the hypothesis that VPA is associated with an enhanced risk of hypoglycemia. To clarify this point, prospective studies with a larger cohort of patients are required that include the evaluation of blood glucose levels under therapy with different anticonvulsive drugs.

In several case reports, the treatment with VPA has been associated with acute pancreatitis both in children and adults [e.g., 33, 34]. It is also known that progressive pancreatic beta-cell failure is the key mechanism leading to diabetes mellitus type 1 and 2 [35]. Thus, an enhanced risk of VPA induced pancreatic damage in this predisposed and potentially vulnerable group of patients can be assumed. However, we could not find a significantly different prevalence of acute pancreatic damage in patients with known (insulin-dependent) diabetes in our cohort.

Sixty-five of 408 patients died during hospitalization (16%). This rate is in line with a reported SE related pooled case fatality rate of 14.9% in a meta-analysis (1). While examining VPA as an independent risk factor for in-hospital mortality, we accounted for potential confounders by including variables that were associated with poor outcome in past investigations [3.14–16.36]. In our study, continuous or repeated infusions of VPA were not independently associated with mortality in either the total cohort or the diabetic group. This observation compares well with other investigations in which older age and a more severe etiology of SE rather than the choice of anticonvulsive treatment strategies predicted mortality [3, 37]. Similar to others [3, 38, 39], the potentially fatal etiology was the strongest predictive factor for mortality in different regression models in the present study (OR = 8.177; 95% CI: 3.776–17.7107; p < 0.001).

The identification of prognostic factors of SE is grounded by the clear evaluation of outcome parameters. Evaluation of outcome must take into account the premorbid state. The premorbid functional state is likely a prognostic factor itself [40]. In the present study, the diabetic group showed a significantly worse premorbid functional state as indicated by the mRS compared to the non-diabetic group. In view of the known somatic complications of diabetes, which include a greater susceptibility to small vessel disease, this observation seems reasonable. The functional outcome in the short term was significantly worse in the diabetic group, too. Although the in-hospital functional change did not differ between the two groups, these results highlight the vulnerability of patients with diabetes, which is associated with a higher risk of an unacceptable outcome. Therefore, the impact of relevant comorbidities as potential prognostic factors should not only be considered in vascular neurological diseases but also in SE.

To our knowledge, this is the first study that evaluated how the presence of diabetes modulates the safety profile of VPA treatment of SE. An additional strength of the study is the collection of a large set of data comprising overall 482 SE episodes, which exceeds the size of most of the study cohorts in previous work.

The main limitations of the study result from its retrospective and single-center design. Relevant adverse events that may occur in the initial phase of treatment with VPA, such as hypotension and respiratory depression, as observed in prospective studies [9], could not be detected due to methodological reasons. In our study, therapy with VPA was not stopped in any of the episodes with early intubation, which highlights the difficulty in clinical practice to distinguish between SE related or treatment related disturbance of consciousness and respiratory depression.
The adverse events that were attributed to the treatment with VPA were identified only indirectly by the decision to discontinue VPA therapy, which likely has led to an underestimation of the rate of adverse events. On the other hand, this ensures that safety issues are considered, which are deemed clinically sufficiently relevant to justify the discontinuation of therapy.

In the choice of covariates for the binary regression model, not all factors known to be associated with in-hospital mortality could be retrieved from the charts, e.g., duration of SE. In view of this, rather than examining independent risk factors, we focused on whether VPA therapy was associated with in-hospital mortality.

Acute pancreatic damage was not observed in patients without a history of a pancreatic disease. The sample size was too small to investigate the question of whether the prevalence of this exceedingly rare adverse event was higher under VPA therapy in diabetic SE patients. Cases of clinically inapparent, mild pancreatic damage may have been missed, because the presence of pancreatic damage was solely based on the diagnosis of the treating clinicians, and full pancreatic testing was not performed in the study population. However, even if we cannot rule out that VPA may increase the risk for pancreatic damage in diabetic patients, its clinical relevance must be weighed carefully against the clinical risk associated with not stopping SE or stopping it too late, and the limited number of available therapies.

The present study included patients with all types of diabetes. This condition potentially leads to an underestimation of relevant adverse events because the subgroup of patients with IDDM was small. The small group size may prevent the recognition of significant differences due to the lack of statistical power. With regard to the small incidence of patients with SE plus IDDM (in this study 13% of the IV VPA cohort), our approach may cover reality to the best possible degree.

The German Instruction for Use prohibits the IV treatment of VPA in patients with IDDM in all marketed preparations [41, 42]. Based on our results, this restriction does not seem justified. Prolonged SE is associated with a significant personal and economic burden [43, 44] highlighting the importance of effective treatment strategies. The present study provides no evidence that patients with IDDM and SE are at higher risk of significant treatment related complications when receiving IV treatment with VPA.

Conclusions

In the present study, tolerability of treatment with IV VPA was similar in patients with or without diabetes. The observation of a higher incidence of drug-associated thrombocytopenia in patients with diabetes should prompt increased awareness of this complication in the clinical setting. The study suggests that diabetes should be considered as a relevant comorbidity that, alone or as an indicator of the presence of other factors, can signal a potentially increased risk of a poor outcome after SE.

Abbreviations

CCI: Charlson comorbidity index; ESETT: Established status epilepticus treatment trial; IDDM: Insulin-dependent diabetes mellitus; IV: Intravenous; mRS: Modified Rankin scale; NIDDM: Non-insulin-dependent diabetes mellitus; SE: Status epilepticus; STESS: Status epilepticus severity score; VPA: Valproic acid.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s42466-022-00212-w.

Acknowledgements

Not applicable.

Author contributions

AM and JC developed the study design and wrote the study protocol. AM, JC and AMr drafted the manuscript. JHH, AM and CA obtained data. JP provided expert advice and supervised statistical analysis. AMr contributed to statistical analysis and to the creation of illustrations. All authors did proofreading the manuscript and approved to its final version.
Funding
The study is funded by the Federal Ministry of Education and Research (No. 01GL1804) and the Department of Neurology, Leipzig University Medical Center.

Availability of data and materials
The datasets analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics committee of the University Leipzig (05/2021, Reference 227/21-ek). Due to the retrospective and non-interventional design patients were not contacted and only data of past hospital stays were used. The need for informed consent was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Leipzig University Medical Center, Liebigstraße 20, 04103 Leipzig, Germany. 2Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany.

Received: 4 May 2022 Accepted: 10 August 2022

References
1. Lv, R. J., Qun, W., Cui, T., Zhu, F., & Shao, X. Q. (2017). Status epilepticus-related etiology, incidence and mortality: A meta-analysis. Epilepsy Research, 136, 12–17.
2. Rossetti, A. O., Logroscino, G., Milligan, T. A., Michaelides, C., Ruffieux, C., & Bromfield, E. B. (2008). Status epilepticus severity score (STESS): a tool to orient early treatment strategy. Journal of Neurology, 253(10), 1561–1566.
3. Reindl, C., Sprügel, M. I., Sembill, J. A., Müller, T. M., Hagen, M., Gerner, S. T., Kuramatsu, J. B., Hamer, H. M., Huttner, H. B., & Madzar, D. (2020). Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus. Seizure, 74, 20–25.
4. Leitinger, M., Höller, G., Kaliss, G., Rohracher, A., Novak, H. F., Höffer, J., Dobeisberger, J., Kuchukhidze, G., & Trinke, E. (2015). Epidemiology-based mortality score in status epilepticus (EMSE). Neurocritical Care, 21(4), 273–282.
5. Trinka, E., Höffer, J., Zerbs, A., & Brigo, F. (2014). Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs, 28(7), 623–639.
6. Meierkord, H., Boon, P., Engelsen, B., Göde, K., Shorvon, S., Tinuper, P., Holtkamp, M., European Federation of Neurological Societies. (2010). EFNS guideline on the management of status epilepticus in adults. European Journal of Neurology, 17(3), 338–355.
7. Minicucci, F., Ferlisi, M., Brigo, D., Mecarelli, O., Meletti, S., Aguglia, A., Michelucci, R., Mastrangelo, M., Specchio, N., Sartori, S., & Tinuper, P. (2020). Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy. Epilepsy and Behavior, 102, 106675.
8. Leitlinie: Deutsche Gesellschaft für Neurologie. Status epilepticus im Erwachsenenalter. https://dgn.org/leitlinien/030-079-status-epilepticus-im-erwachsenenalter-2020/.
9. Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinerz, C., Cock, H., Fountain, N., Connor, J. T., Silbergleit, R., & NETT and PECARN Investigators. (2020). Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. The Lancet, 395(10231), 1217–1224.
10. Heidemann, C., Kuhnert, R., Born, S., & Scheidt-Nave, C. (2017). 12-Monats-Prävalenz des bekannten diabetes mellitus in Deutschland. Journal of Health Monitoring. https://doi.org/10.17886/RKI-GBE-2017-008
11. Rankin, J. (1957). Cerebral vascular accidents in patients over the age of 60 II. Prognosis. Scottish Medical Journal, 2, 200–215.
12. Charlton, M. E., Pompei, P., Ales, K. L., & Mackenize, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.
13. Madzar, D., Geyer, A., Knappe, R. U., Gollwitzer, S., Kuramatsu, J. B., Gerner, S. E., Hamer, H. M., & Huttner, H. B. (2016). Association of seizure duration and outcome in refractory status epilepticus. Journal of Neurology, 263(3), 485–491.
14. Tatlidil, I., Ture, H. S., & Akhan, G. (2020). Factors affecting mortality of refractory status epilepticus. Acta Neurologica Scandinavica, 141(2), 123–131.
15. Rossetti, A. O., Hurwitz, S., Logroscino, G., & Bromfield, E. B. (2006). Prognosis of status epilepticus: Role of etiology, age, and consciousness impairment at presentation. Journal of Neurology, Neurosurgery and Psychiatry, 77(6), 611–615.
16. Global, A., Fan, W., & Wang, N. D. (2019). Epidemiology of diabetes mellitus and cardiovascular disease. Current Cardiology Reports, 21(4), 21.
17. Ferrelli, E., Pessanha, F. P. A. S., & Marchesi, J. C. L. S. (2014). Diabetes and exercise in the elderly. Medicine and Sport Science, 60, 122–129.
18. Koubeissi, M., & Alshekhlee, A. (2007). In-hospital mortality of generalised convulsive status epilepticus: A large US sample. Neurology, 69(9), 886–893.
19. Alvarez, V., Januel, J. M., Burnand, B., & Rossetti, A. O. (2012). Role of comorbidities in outcome prediction after status epilepticus. Epilepsia, 53(S), e89–92.
20. Belluzzo, M., Furlanis, G., Stragapede, L., & Monti, F. (2017). Role of comorbidities and in-hospital complications in short-term status epilepticus outcome. Clinical Neurology and Neurosurgery, 154, 13–18.
21. Mendiratta, P., Dayama, N., Wei, J. Y., & Prodhon, P. (2019). Status epilepticus among older adults in the United States. Geriatrics, 4(3), 45. Basel.
22. Tammako, S., Saybungkla, P., Sirkarn, P., Sawanyawisuth, K., Integrated Epilepsy Research Group. (2018). Predictors of long-term mortality in status epilepticus. Epilepsy and Behavior, 84, 114–117.
23. Devinsky, O., Lempik, J., Willmore, L. J., Pelloch, J. M., Dean, C., Gates, J., & Ramsay, R. E. (1995). Safety of intravenous valproate. Annals of Neurology, 38, 670–674.
24. Chen, C. Y., Lee, M. Y., Lin, K. D., Hsu, W. H., Lee, Y. J., Hisao, P. J., & Shin, S. J. (2015). Diabetes mellitus increases severity of thrombocytopenia in dengue-infected patients. International Journal of Molecular Sciences, 16(2), 3820–3830.
25. Prechel, M., Hudce, S., Lowden, E., Escalante, V., Emanuele, N., Emanuele, M., & Walenga, J. M. (2018). Profiling heparin-induced thrombocytopenia (HIT) antibodies in hospitalized patients with and without diabetes. Clinical and Applied Thrombosis/Hemostasis, 24(9), 2945-3005.
26. Barr, R. D., Copeland, S. A., Stockwell, M. L., Morris, N., & Kelton, J. C. (1982). Valproic acid and immune thrombocytopenia. Archives of Disease in Childhood, 57(9), 681–684.
27. Verroni, A., D’Egidio, C., Mohan, A., Coppola, G., & Ciarelli, F. (2011). Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obesity Reviews, 12(5), e32-43.
28. Elmslie, J. L., Porter, R. J., Joyce, P., Hunt, J. P., Shand, B. I., & Scott, R. S. (2009). Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Australian and New Zealand Journal of Psychiatry, 43(1), 53–60.
29. Fathallah, N., Slim, R., Labir, S., Hmouda, H., & Sælæn, C. B. (2015). Drug-induced hyperglycemia and diabetes. Drug Safety, 38(12), 1153–1168.
30. Khan, K. S., & Jena, G. (2016). Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat. Biochimie, 125, 42–52.
31. Terasmaa, A., Soomets, U., Oflijan, J., Punapat, M., Hansen, M., Matta, V., Ehrlich, K., Must, A., Koks, S., & Vasar, E. (2011). W61 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin. Journal of Physiology and Biochemistry, 67(3), 381–390.
33. Gerstner, T., Büsing, D., Bell, N., Longin, E., Kasper, J. M., Klostermann, W., Hebing, B., Hanefeld, F., Eckel, Z., Hoffmann, R., Bettendorf, U., Weidner, B., Wiemer-Kruel, A., Brockmann, K., Neumann, F. W., Sandreser, T., Wolff, M., & König, S. (2007). Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. Journal of Gastroenterology, 42(1), 59–68.

34. Chapman, S. A., Wacksman, G. P., & Patterson, B. D. (2001). Pancreatitis associated with valproic acid: A review of the literature. Pharmacotherapy, 21(12), 1549–1560.

35. Eizirik, D. L., & Colli, M. L. (2020). Revisiting the role of inflammation in the loss of pancreatic β-cells in T1DM. Nature Reviews Endocrinology, 16(11), 611–612.

36. Vilella, L., Gonzalez Cuevas, M., Quintana Luque, M., Toledo, M., Sueiras Gil, M., Guzman, L., Salas Puig, J., & Santamarina, P. E. (2018). Prognosis of status epilepticus in elderly patients. Acta Neurologica Scandinavica, 137(3), 321–328.

37. Rosetti, A. O., Logroscino, G., & Bromfield, E. B. (2005). Refractory status epilepticus. Effect of treatment aggressiveness on prognosis. Archives of Neurology, 62(11), 1698–1702.

38. Leitinger, M., Tirirka, E., Giovannini, G., Zimmermann, G., Florea, C., Rohracher, A., Kalis, G., Neuray, C., Kreidenhuber, R., Höfler, J., Kuchukhidze, G., Granbickler, C., Dobesberger, J., Novak, H. F., Pilz, G., Meletti, S., & Siebert, U. (2019). Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. Epilepsia, 60(1), 53–62.

39. Alvarez, V., Januel, J. M., Burnand, B., & Rossetti, A. O. (2011). Second-line status epilepticus treatment: Comparison of phenytoin, valproate, and levetiracetam. Epilepsia, 52, 1292–1296.

40. Gonzalez-Cuevas, M., Santamarina, E., Toledo, M., Quintana, M., Sala, J., Sueiras, M., Guzman, L., & Salas-Puig, J. (2016). A new clinical score for the prognosis of status epilepticus in adults. European Journal of Neurology, 23(10), 1534–1540.

41. Fachinformation Sanofi Ergenyl intravenös (2021). https://mein.sanofi.de/produkte/Ergenyl-intravenoes-Vial/Downloads?id=22df894a-0ef1-461d-be30-3647cc0d0740.

42. Gebrauchsinformation Orfiril 100mg/ml Infusionslösung (2021). https://www.desitin.de/wp-content/uploads/2019/09/Orfiril_i.v_GI.pdf.

43. Guterman, E. L., Betjemann, J. P., Aimetti, A., Li, J. W., Wang, Z., Yin, D., Hulihan, J., Lyons, T., Mivasato, G., & Strelitzky, A. (2021). Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurology, 78(5), 588–595.

44. Kortland, L. M., Alfter, A., Bähr, O., Carl, B., Dodel, R., Freiman, T. M., Hubert, K., Jahnke, K., Knake, S., von Padowelis, F., Reeve, J. P., Runge, U., Serfl, C., Steinmetz, H., Rosenow, F., & Strzelczyk, A. (2016). Costs and cost-driving factors for acute treatment of adults with status epilepticus. A multicenter cohort study from Germany. Epilepsia, 57(12), 2065–2066.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.